Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL)

Horwitz, SM; Scarisbrick, JJ; Dummer, R; Duvic, M; Kim, YH; Walewski, J; Whittaker, S; Quaglino, P; Zinzani, PL; Wolter, P; Eradat, H; Sanches, JA; Ortiz-Romero, PL; Akilov, OE; Trotman, J; Taylor, K; Dalle, S; Weichenthal, M; Fisher, DC; Stadler, R; Feldman, TA; Kuzel, TM; Gru, AA; Wang, YH; Palanca-Wessels, MC; Lin, HM; Liu, Y; Little, M; Prince, HM